Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
The present invention relates to a method for controlling obesity and diseases caused by obesity.
The peptide hormone endothelin is known for its strong vasoconstrictor properties. Endothelin receptor antagonists are therefore mainly being tested in cardiovascular pathologies.
The invention relates
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
The present invention relates to novel pyrazolopyridine compound and a pharmaceutically acceptable salt thereof.
More particularly, it relates to novel pyrazolopyridine compound and a pharmaceutically acceptable salt thereof, which are adenosine antagonists and possess various pharmaceutical actions
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
FIELD OF THE INVENTION
The present invention relates to certain novel compounds, methods for preparing compounds, compositions, intermediates and derivatives thereof and for treating conditions such as cancer, arthritis, inflammatory airway disease, and metabolic disorders. More particularly, the
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
TECHNICAL FIELD
The present invention focuses on definition of pharmaceutical compositions and proposed method for the treatment of metabolic syndrome, diabetes mellitus and aging. Compounds and compositions of natural origin are disclosed in the description. More particularly, this invention
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
SEQUENCE LISTING
The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Jul. 28, 2016, is named Seq_Listing_121301_01202.txt and is 116,250 bytes in
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
PRIORITY
This application is a national phase filing of the Patent Cooperation Treaty (PCT) application # PCT/IB2013/050904 titled COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC SYNDROME filed on Feb. 3, 2013 Published with WIPO Publication # WO/2013/167996, which further claims priority to
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
PRIORITY
The present application claims the benefit of Indian Provisional Patent Application No. 1836/CHE/2012 filed on 10 May 2012 and the International Application No. PCT/IB2013/050907 filed on 3 Feb. 2013; the entire disclosure of which is relied on for all purposes and is incorporated into this
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
FIELD OF THE INVENTION
The present invention relates to compounds which are inhibitors of sodium dependent glucose co-transporter-2 (SGLT-2), methods of making them, and uses thereof.
BACKGROUND OF THE INVENTION
According to the World Health Organization (WHO), in 2009, more than 220 million people
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
This application is a U.S. national stage of International Application No. PCT/JP03/03115 filed Mar. 14, 2003.
TECHNICAL FIELD
The present invention is useful in medical fields. In more detail, novel pyridone derivatives of the present invention have an effect as neuropeptide Y receptor antagonists
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a U.S. National Phase application under 35 U.S.C. .sctn. 371 of PCT Application No. PCT/JP2004/013768, filed Sep. 21, 2004, which claims priority under 35 U.S.C. .sctn. 119 from Japanese Application No. JP2003-330758, filed Sep. 22,
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
TECHNICAL FIELD
The present invention relates to a novel piperidine derivative, to a histamine-H3 receptor antagonist containing the novel piperidine derivative as an active ingredient thereof, and to a preventive or remedy for metabolic system diseases, circulatory system diseases, central or
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
The present invention relates to novel pyrazolopyridine compound and a pharmaceutically acceptable salt thereof.
More particularly, it relates to novel pyrazolopyridine compound and a pharmaceutically acceptable salt thereof, which are adenosine antagonists and posses various pharmaceutical actions
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
FIELD OF THE INVENTION
The present invention relates to certain novel compounds, methods for preparing compounds, compositions, intermediates and derivatives thereof and for treating conditions such as cancer, arthritis, inflammatory airway disease, and metabolic disorders. More particularly, the
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
FIELD OF THE INVENTION
The present invention relates to certain novel compounds, methods for preparing compounds, compositions, intermediates and derivatives thereof and for treating conditions such as cancer, arthritis, inflammatory airway disease, and metabolic disorders. More particularly, the
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
FIELD OF THE INVENTION
The present invention relates to certain novel compounds, methods for preparing compounds, compositions, intermediates and derivatives thereof and for treating conditions such as cancer, arthritis, inflammatory airway disease, and metabolic disorders. More particularly, the
Išsamiausia vaistinių žolelių duomenų bazė, paremta mokslu
Dirba 55 kalbomis
Žolelių gydymas, paremtas mokslu
Vaistažolių atpažinimas pagal vaizdą
Interaktyvus GPS žemėlapis - pažymėkite vaistažoles vietoje (netrukus)
Skaitykite mokslines publikacijas, susijusias su jūsų paieška
Ieškokite vaistinių žolelių pagal jų poveikį
Susitvarkykite savo interesus ir sekite naujienas, klinikinius tyrimus ir patentus
Įveskite simptomą ar ligą ir perskaitykite apie žoleles, kurios gali padėti, įveskite žolę ir pamatykite ligas bei simptomus, nuo kurių ji naudojama. * Visa informacija pagrįsta paskelbtais moksliniais tyrimais